Controversies regarding long-acting β2-agonists.

Area of Science:

• Pulmonology
• Pharmacology
• Genetics

Background:

• Current asthma guidelines recommend long-acting beta-agonists (LABAs) as add-on therapy for patients not controlled by inhaled corticosteroids (ICS).
• However, data suggest a potential increase in morbidity and mortality associated with LABA use.
• This highlights a need to investigate factors influencing patient response to LABAs.

Purpose of the Study:

• To review the literature on the efficacy and safety of long-acting beta-agonists (LABAs) as add-on therapy to inhaled corticosteroids (ICS).
• To explore potential genotypic or phenotypic differences that may explain varied responses to LABAs in asthma patients.

Main Methods:

• Literature review of studies examining LABA efficacy and safety in asthma.
• Analysis of current asthma treatment guidelines (GINA, NHLBI).
• Examination of data regarding patient subgroups and their responses to LABA/ICS therapy.

Main Results:

• Combination therapy of LABAs and ICS improves asthma control and reduces exacerbation rates.
• Concerns exist regarding potential increased risks with LABAs, particularly in certain populations like steroid-naïve patients and African Americans.
• Current evidence does not clearly identify genotypic or phenotypic factors explaining differential responses to LABAs.

Conclusions:

• LABAs should not be used as monotherapy or without optimized inhaled corticosteroid doses.
• While most asthmatics benefit from LABA addition, a subset may not experience benefits or could face risks.
• Further research is needed to elucidate the reasons for variable responses to long-acting beta-agonists in asthma management.